Soleno Therapeutics (SLNO) Cost of Revenue (2016 - 2017)
Historic Cost of Revenue for Soleno Therapeutics (SLNO) over the last 4 years, with Q2 2017 value amounting to $42000.0.
- Soleno Therapeutics' Cost of Revenue fell 7454.55% to $42000.0 in Q2 2017 from the same period last year, while for Dec 2017 it was $69000.0, marking a year-over-year decrease of 9018.49%. This contributed to the annual value of $26000.0 for FY2017, which is N/A changed from last year.
- As of Q2 2017, Soleno Therapeutics' Cost of Revenue stood at $42000.0, which was down 7454.55% from $27000.0 recorded in Q1 2017.
- In the past 5 years, Soleno Therapeutics' Cost of Revenue registered a high of $538000.0 during Q1 2016, and its lowest value of $12000.0 during Q2 2014.
- Its 4-year average for Cost of Revenue is $250529.9, with a median of $165000.0 in 2016.
- As far as peak fluctuations go, Soleno Therapeutics' Cost of Revenue soared by 411666.67% in 2015, and later tumbled by 9498.14% in 2017.
- Quarter analysis of 4 years shows Soleno Therapeutics' Cost of Revenue stood at $156359.0 in 2014, then surged by 218.8% to $498470.0 in 2015, then tumbled by 66.9% to $165000.0 in 2016, then crashed by 74.55% to $42000.0 in 2017.
- Its Cost of Revenue stands at $42000.0 for Q2 2017, versus $27000.0 for Q1 2017 and $165000.0 for Q2 2016.